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Buruli Ulcer in 
Long-Term Traveler 
to Senegal
To the Editor: Buruli ulcer (BU) 
is caused by infection of subcutaneous 
fat with the environmental pathogen 
Mycobacterium ulcerans. BU has been 
reported or suspected in more than 30 
countries. It has never been reported 
in Senegal and Guinea-Bissau (1). We 
report a case of travel-associated BU 
in a French traveler to Senegal.
The patient was a 24-year-old 
Caucasian man who came to the Uni-
versity Hospital of Bordeaux, France, 
with a nonhealing lesion on the ante-
rior left leg that had been present for 
≈12 weeks. The patient had traveled in 
Senegal to the border of Guinea-Bis-
sau from September 2006 through Au-
gust 2007. His trip had begun in Dakar 
and proceeded south to the districts of 
Kaolack, Toubacouta, and Casamance. 
The patient stayed in Casamance dur-
ing the rainy season from June 2007 
through August 2007. He had been 
working on construction of wood dug-
outs, had been bare-legged regularly, 
and had been in contact with stagnant 
water.
He  ﬁ  rst noticed a lesion during 
June 2007, which had gradually in-
creased to a small, centrally crusted 
ulcer. By the end of August 2007 
(week 8 of the lesion), skin examina-
tion showed a 3 × 6-cm necrotizing 
ulcer with central crusting and an ery-
thematous border (Figure). The lesion 
was not warm or tender but generated 
a seropurulent discharge. Concurrent-
ly, palpable left inguinal lymph nodes 
were observed.
Bacteriologic swabs identiﬁ  ed 
Staphylococcus aureus and group A 
Streptoccocus pyogenes. Two punch-
biopsy specimens were taken from 
the border of the lesion. Histologic 
analysis showed nonspeciﬁ  c  acute 
and chronic dermal inﬂ  ammation 
with necrotizing granulomas that ex-
tended into the subcutaneous tissues, 
suggestive of infection with atypical 
Mycobacterium  spp. Bacteriologic 
examination did not identify acid-fast 
bacilli (negative direct smear result 
after Ziehl-Neelsen staining) or other 
speciﬁ  c microorganisms (negative di-
rect smear results after periodic acid–
Schiff, Giemsa, and Gram staining). 
Tissue specimens were placed into 
BACTEC 12B broth (Becton Dickin-
son, Franklin Lakes, NJ, USA) (incu-
bated at 35°C) and onto Löwenstein-
Jensen slants (incubated at 30°C). No 
growth was detected after 42 days. On 
the basis of clinical ﬁ  ndings, we sus-
pected a diagnosis of BU.
Taq-Man real-time quantita-
tive PCR that used primers for 2 M. 
ulcerans–speciﬁ   c genes (insertion 
sequence  2404 and ketoreductase 
B gene) (2,3) and negative controls 
showed positive results for DNA from 
both biopsy specimens. A normalized 
standard curve was constructed, which 
indicated a bacterial load of ≈6 × 103 
organisms/g of tissue.
Laboratory investigations indi-
cated a total leukocyte count of 16,400 
cells/μL (reference range 3,600–
10,000 cells/μL) and a C-reactive pro-
tein level of 0.59 mg/mL (reference 
value <0.01 mg/mL). Results of radio-
logic investigations were normal. The 
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Figure. Ulcer (3 × 6 cm) on anterior side of the left leg of the patient, showing an 
erythematous border.LETTERS
patient was treated with rifampin (600 
mg/day) and moxiﬂ  oxacin (400 mg/
day) for 12 weeks. Additional surgical 
excision was planned 4 weeks after 
treatment was begun. Unfortunately, 
15 days later, the patient was lost to 
follow-up.
BU has been reported in many 
West African countries, with Guinea 
being the northern limit of reported 
cases. Detection of this case of BU 
suggests that the region in West Af-
rica endemic for this disease has been 
underestimated or is expanding. In-
fection in the traveler may have oc-
curred in Casamance, if one assumes 
an incubation period of 6 weeks to 3 
months. Further cases should be ac-
tively sought in this region and ad-
joining districts visited to evaluate the 
geographic extent of the disease.
The environmental reservoir and 
mode of transmission of BU in our 
patient are unknown. Exposure of un-
protected skin with stagnant or slow-
ﬂ  owing water is linked with BU. Our 
patient reported prolonged contact 
with water during his occupation. Re-
cent studies implicating aquatic preda-
tor insects (4,5) and mosquitoes (6) in 
transmission of BU suggest that use of 
insect repellents and protective cloth-
ing may help prevent infection.
The diagnosis of BU in this pa-
tient relied on the PCR detection of 2 
M. ulcerans–speciﬁ  c genes; this pro-
cedure is considered adequate (7,8). 
The relatively low number of organ-
isms detected may explain the nega-
tive acid-fast bacilli smear and culture 
results (9). Our report of M. ulcerans 
infection from Senegal is not surpris-
ing because southern Senegal shares 
similar ecologic features with neigh-
boring affected countries, especially 
during the heavy rainy season.
Although BU is a disease that 
affects mainly persons in recognized 
disease-endemic areas, this case em-
phasizes that tropical skin ulcers 
should be considered in differential 
diagnosis of BU in travelers returning 
from disease-endemic countries (1,10). 
Diagnostic delays can be avoided by 
use of M.  ulcerans–speciﬁ   c PCR, a 
test available from World Health Or-
ganization collaborating laboratories, 
which enables rapid conﬁ  rmation of 
diagnosis of BU.
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